Q: What scientific research and published information support the effectiveness of Neurocet’s method of pain relief and control?

A: Here is just some of the information available on Neurocet’s pain-relieving power:

Endorphins are the body’s natural, pain fighting powerhouses.

As reported in the Los Angeles Times: “In 1975, two Scottish researchers, Hans W. Kosterlitz and John Hughes, identified encephalin, the first of a family of chemicals they named endorphins. These naturally occurring chemicals can relieve pain and create a feeling of euphoria, such as the well-known ‘runner's high.’ “

Dr. Avram Goldstein, professor of pharmacology at Stanford University and one of the discoverers of endorphins, was noted as saying: “When nature makes anything that powerful, you’ve got to believe there’s an important reason for it.”

In a report about the role of endorphins, the Public Broadcasting System (PBS) said that endorphins have been shown to be 48 times more powerful than morphine.

The website Medical Discoveries describes endorphins and enkephalins as the body’s natural painkillers. You can read the full text of an article about this critical medical discovery here:

A research team at UCLA Department of Medicine headed by Dr. Don Catlin, a pioneering and well-known hormone specialist, injected endorphins into pain patients and found they could both help relieve pain and help with narcotic withdrawal symptoms. (As reported in the Dec. 12, 1977, issue of the Chicago Tribune.)

Endorphins can travel at speeds of 175 miles an hour in your body. The authoritative New York State Wadsworth Center says: “The Neuron (endorphin) sends signals faster than a speeding bullet …”

Low levels of endorphins may explain why people suffer from so much pain.

Author and cardiologist Dr. Arnold Fox, M.D., reported on the following five important studies:

The Journal of Rheumatology suggests that low endorphin levels can contribute to arthritis: Blood samples from patients with a wide variety of arthritic conditions were reported to be shockingly low in endorphins.

Doctors and esteemed researchers Lars Terenius and Agenta Wahlstrom in Sweden found that the activity of a natural “morphine-like” factor was about 50 percent lower in chronic pain patients.

A study of migraine sufferers revealed endorphin losses of 50 percent to 80 percent. The worse the migraine condition, the lower the endorphin level.

Researchers looked for endorphin activity in the spinal fluid from 80 chronic pain patients, finding a deficiency in endorphin levels when compared to healthy volunteers.

In a separate study, both the beta-endorphin and beta-lipotropin levels from 24 chronic pain patients revealed up to an 87-percent loss of beta-endorphin and just over two thirds less beta-lipotropin than the pain-free participants.

DL-phenylalanine (DLPA), one of Neurocet’s three key ingredients, has the ability to power up these pain-relieving endorphins.

A study by Dr. Arnold Fox, M.D., found that DLPA relieved pain 26 times longer than an average of five commonly prescribed pain drugs and five popular arthritis drugs that worked for just 4.5 hours. Dr. Fox said: “DLPA ‘is a rare substance known to effectively and safely neutralize the enzymes in the brain that destroy endorphins.’ ”

In one in vitro test, DLPA tripled endorphin levels within 90 minutes.

DLPA also helps to greatly extend your endorphins’ life-span. This article in OM Times Health Magazine reports, “It’s is a great pain killer … it activates endorphins and helps end pain.”

AprèsFlex®’s Boswellia has a proven track record for reducing pain.

New York University Medical School researchers found a “significant improvement” in arthritis symptoms. In a double-blind study of 30 people, researchers compared Boswellia against a placebo. The results showed a significant improvement in knee pain, knee mobility and walking distance compared to the placebo.

In a double-blind, randomized, placebo-controlled study, 59 subjects with pain were given 100 mg of AprèsFlex® or a placebo daily for 30 days. Three different tests were administered to measure pain, stiffness and physical function.

  • AprèsFlex® showed a 14.8 percent better reduction in pain than placebo starting in 5 days.
  • The AprèsFlex® group reported a 40.1 percent improvement in pain relief, a 41.3 percent improvement in stiffness, and a 38.8 percent improvement in physical function after 30 days.


FruiteX-B® Calcium Fructoborate is shown to reduce inflammation, reduce joint stiffness and pain, and to improve flexibility.

In a clinical test at the Orthopedic Clinic at University Novi Sad, people with mild to medium forms of osteoarthritis taking 6 mg dose of FruiteX-B®, had an average pain reduction of 62.5 percent. Average joint stiffness fell 87.5 percent.  Inflammation-causing CRP, or C-reactive protein, was cut by 61 percent.

Not only were pain, stiffness and inflammation reduced, but mobility and flexibility were increased. A whopping 71.3 percent reported better movement and flexibility. These results are from the Orthopedic Clinic at University Novi Sad.

Wellness Resources says, “Calcium Fructoborate (FruiteX-B®) clearly has antioxidant activity. Antioxidants protect your body structures.” They also say: “FruiteX-B® also significantly improves the status and function of vitamin D and calcium within your body, helping both bones and joints.”

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Have more questions? Submit a request